Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT01090414
An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies
Clinical Associate Professor, Medicine - Hematology
Clinical Associate Professor, Medicine - Oncology
Moghadam Family Professor
Clinical Associate Professor, Medicine - Hematology
Professor of Medicine (Hematology)
Key Inclusion Criteria:
- Patients with hematologic malignancies completing a prior idelalisib study with a
clinical benefit are eligible
- Women of childbearing potential must have a negative pregnancy test to be eligible
- Male patients, and female patients of childbearing potential, must agree to use
method(s) of contraception specified in the protocol
Key Exclusion Criteria:
- Patients who are unwilling or unable to comply with the protocol are not eligible
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
drug: Idelalisib
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061